Tier 2 — strong

Nicotinamide riboside and pterostilbene reduces markers of hepatic inflammation in NAFLD: A double-blind, placebo-controlled clinical trial

Dellinger RW, Holmes HE, Hu-Seliger T, Butt RW, Harrison SA, Mozaffarian D, Chen O, Guarente L
Hepatology (Baltimore, Md.) 2023 78; 3; 863-877

Bibliography

PubMed
PMID 36082508
DOI
10.1002/hep.32778
Funding
Funding details are not specified in the accessible publication information.
Competing interests
A complete competing-interest declaration is not specified in the accessible publication information.

Study snapshot

DesignRandomized controlled study of a multi-ingredient or combined intervention
ModelHuman participants
Sample111 adults with NAFLD
InterventionStandard or double-dose NR/pterostilbene combination versus placebo
Duration6 months
EndpointsLiver fat fraction; ALT and GGT; ceramides

What the study showed, in plain terms

The combination did not improve the primary liver-fat endpoint. Selected liver-enzyme and lipid secondary outcomes improved at the standard dose.

Key findings

The combination did not improve the primary liver-fat endpoint. Selected liver-enzyme and lipid secondary outcomes improved at the standard dose.

What this study can and cannot tell us

No consistent dose-response and multiple secondary outcomes; lower enzymes are not proof of reduced fibrosis or disease progression.

Related papers in the corpus

Tier 4
Nicotinamide riboside and pterostilbene reduces frequency and severity of undesirable symptoms of the menopause transition: an open-label, pilot clinical trial
Holmes HE et al. · Frontiers in aging · 2026
Tier 2
Effect of the Mediterranean diet supplemented with nicotinamide riboside and pterostilbene and/or coconut oil on anthropometric variables in amyotrophic lateral sclerosis. A pilot study
Carrera-Juliá S et al. · Frontiers in nutrition · 2023
Tier 2
A randomized placebo-controlled trial of nicotinamide riboside and pterostilbene supplementation in experimental muscle injury in elderly individuals
Jensen JB et al. · JCI insight · 2022
Tier 2
Nicotinamide riboside with pterostilbene (NRPT) increases NAD + in patients with acute kidney injury (AKI): a randomized, double-blind, placebo-controlled, stepwise safety study of escalating doses of NRPT in patients with AKI
Simic P et al. · BMC nephrology · 2020
Tier 2
Efficacy and tolerability of EH301 for amyotrophic lateral sclerosis: a randomized, double-blind, placebo-controlled human pilot study
de la Rubia JE et al. · Amyotrophic lateral sclerosis & frontotemporal degeneration · 2019
Tier 2
Repeat dose NRPT (nicotinamide riboside and pterostilbene) increases NAD + levels in humans safely and sustainably: a randomized, double-blind, placebo-controlled study
Dellinger RW et al. · NPJ aging and mechanisms of disease · 2017

Citation network

Articles citing this research paper

2 articles

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology